Suppr超能文献

吸入性双胍类药物与mTOR抑制用于流感和冠状病毒(综述)

Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review).

作者信息

Lehrer Steven

机构信息

Fermata Pharma Inc., New York, NY 10023-7909, USA.

出版信息

World Acad Sci J. 2020 May;2(3). doi: 10.3892/wasj.2020.42. Epub 2020 Mar 29.

Abstract

The mammalian target of rapamycin (mTOR) signaling pathway senses and responds to nutrient availability, energy sufficiency, stress, hormones and mitogens to modulate protein synthesis. Rapamycin is a bacterial product that can inhibit mTOR via the PI3K/AKT/mTOR pathway. mTOR signaling is necessary for the development of influenza and modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. In one human study, it was found that the treatment of severe H1N1 influenza‑related pneumonia with rapamycin and steroids improved the outcome. However, in other studies, immunosuppression with systemic steroids, and possibly rapamycin as well, was associated with an increased morbidity/mortality and a prolonged viral replication. In order to avoid the systemic side-effects, some investigators have postulated that the inhalation of rapamycin would be desirable. However, the inhalation of rapamycin, with its well-documented lung toxicity, could be contraindicated. Another class of drug, biguanides, can also inhibit mTOR, but have no lung toxicity. Biguanides are widely used small molecule drugs prescribed as oral anti-diabetics that have exhibited considerable promise in oncology. During the 1971 outbreak of influenza, diabetic patients treated with the biguanides, phenformin and buformin, had a lower incidence of infection than diabetics treated with sulfonylureas or insulin. Both buformin and phenformin reduce the mortality of influenza in mice; phenformin is less effective than buformin. The inhalation of buformin or phenformin for influenza may be an effective novel treatment strategy that would limit the risk of systemic side-effects associated with biguanides due to the low inhaled dose. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019-2020 coronavirus outbreak. It is primarily spread between individuals via small droplets emitted from infected individuals when breathing or coughing. PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent a novel drug target for therapeutic intervention strategies. The present review article discusses the effects of biguanides on influenza and coronavirus.

摘要

雷帕霉素的哺乳动物靶点(mTOR)信号通路可感知并响应营养物质的可利用性、能量充足程度、应激、激素和有丝分裂原,从而调节蛋白质合成。雷帕霉素是一种细菌产物,可通过PI3K/AKT/mTOR途径抑制mTOR。mTOR信号对于流感的发展是必需的,并调节抗体反应,为致命性流感病毒感染提供交叉保护性免疫。在一项人体研究中,发现用雷帕霉素和类固醇治疗严重的H1N1流感相关肺炎可改善治疗结果。然而,在其他研究中,全身用类固醇进行免疫抑制,雷帕霉素可能也如此,与发病率/死亡率增加以及病毒复制延长有关。为了避免全身副作用,一些研究人员推测吸入雷帕霉素可能是可取的。然而,鉴于雷帕霉素有确凿记录的肺毒性,吸入雷帕霉素可能是禁忌的。另一类药物双胍类也可抑制mTOR,但没有肺毒性。双胍类是广泛使用的小分子药物,作为口服抗糖尿病药,在肿瘤学方面已展现出相当大的前景。在1971年流感爆发期间,用双胍类药物苯乙双胍和丁双胍治疗的糖尿病患者感染发生率低于用磺脲类或胰岛素治疗的糖尿病患者。丁双胍和苯乙双胍均可降低小鼠流感的死亡率;苯乙双胍的效果不如丁双胍。吸入丁双胍或苯乙双胍治疗流感可能是一种有效的新治疗策略,由于吸入剂量低,可限制与双胍类相关的全身副作用风险。2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的传染病,该病毒与SARS病毒密切相关。该疾病是2019 - 2020年冠状病毒爆发的病因。它主要通过感染者呼吸或咳嗽时喷出的小飞沫在人与人之间传播。PI3K/AKT/mTOR信号反应在中东呼吸综合征冠状病毒(MERS-CoV)感染中起重要作用,可能代表治疗干预策略的新药物靶点。本综述文章讨论了双胍类对流感和冠状病毒的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d6/7170270/df7399428394/nihms-1579720-f0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验